Japanese pharmaceutical company Takeda has announced a strategic collaboration with Biological E, a prominent vaccines and biologics company in India, to manufacture Takeda’s dengue vaccine, TAK-003.
This strategic partnership aims to produce up to 50 million doses per year by 2030, addressing the global public health imperative. It represents a significant milestone in combating the worldwide threat of dengue fever, aligning with the World Health Organization’s target to achieve zero dengue-related fatalities by 2030.
The collaboration will bolster manufacturing capabilities, ensuring a sustainable global vaccine supply. Biological E will scale up production capacity to potentially reach 50 million doses annually, advancing Takeda’s goal of manufacturing 100 million doses annually within the decade.
The announcement of this partnership took place at BioAsia 2024, a regional life sciences and healthcare forum organized by the Government of Telangana. Anumula Revanth Reddy, the Chief Minister of Telangana, expressed delight in Hyderabad being chosen as the facility location for manufacturing the dengue vaccine resulting from the Takeda-Biological E partnership.
Recently, the World Health Organization’s Strategic Advisory Group of Experts on Immunization recommended Takeda‘s dengue vaccine for introduction in areas with high dengue prevalence and transmission intensity, aiming to maximize its public health impact.
Dion Warren, Head of India and Southeast Asia Multi-country Organization at Takeda, expressed enthusiasm for the potential of integrated dengue protection to enhance lives across India, Southeast Asia, and beyond, with recent vaccine approvals in Thailand, Indonesia, and Malaysia.
Read More: Click Here
